Q4 Earnings Estimate for Genmab A/S Issued By HC Wainwright

Genmab A/S Sponsored ADR (NASDAQ:GMAB) – HC Wainwright raised their Q4 2026 earnings per share (EPS) estimates for Genmab A/S in a note issued to investors on Thursday, October 29th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of $0.46 for the quarter, up from their prior forecast of $0.46. HC Wainwright has a “Buy” rating and a $70.00 price objective on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.22 per share. HC Wainwright also issued estimates for Genmab A/S’s Q1 2027 earnings at $0.35 EPS, Q2 2027 earnings at $0.59 EPS, Q3 2027 earnings at $0.61 EPS and Q4 2027 earnings at $0.61 EPS.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.54 EPS for the quarter, beating the consensus estimate of $0.37 by $0.17. The business had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.12 billion. Genmab A/S had a return on equity of 14.89% and a net margin of 19.08%.

A number of other research firms have also recently commented on GMAB. Truist Financial reissued a “buy” rating and issued a $67.00 price target (up from $45.00) on shares of Genmab A/S in a report on Thursday. JPMorgan Chase & Co. upgraded Genmab A/S from a “neutral” rating to an “overweight” rating in a research note on Monday. Guggenheim increased their price objective on shares of Genmab A/S from $45.00 to $54.00 and gave the company a “buy” rating in a report on Monday, October 5th. TD Cowen lifted their price objective on shares of Genmab A/S from $43.00 to $52.00 and gave the company a “buy” rating in a research report on Monday. Finally, Weiss Ratings upgraded shares of Genmab A/S from a “hold (c)” rating to a “hold (c+)” rating in a research report on Tuesday, September 1st. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $49.06.

Genmab A/S Stock Performance

NASDAQ:GMAB opened at $56.49 on Friday. The company has a current ratio of 2.46, a quick ratio of 2.44 and a debt-to-equity ratio of 0.81. Genmab A/S has a 12-month low of $23.62 and a 12-month high of $59.97. The stock has a 50-day moving average price of $36.64 and a 200 day moving average price of $30.47. The stock has a market capitalization of $35.25 billion, a P/E ratio of 41.22, a P/E/G ratio of 2.47 and a beta of 0.81.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Integrated Wealth Concepts LLC bought a new stake in shares of Genmab A/S in the second quarter worth about $31,000. V Square Quantitative Management LLC purchased a new stake in shares of Genmab A/S in the first quarter worth about $34,000. Nykredit A S purchased a new stake in shares of Genmab A/S in the second quarter worth about $58,000. GAMMA Investing LLC boosted its stake in Genmab A/S by 16.4% during the second quarter. GAMMA Investing LLC now owns 3,978 shares of the company’s stock valued at $109,000 after buying an additional 561 shares during the last quarter. Finally, EverSource Wealth Advisors LLC boosted its stake in Genmab A/S by 51.6% during the first quarter. EverSource Wealth Advisors LLC now owns 4,597 shares of the company’s stock valued at $123,000 after buying an additional 1,565 shares during the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Key Genmab A/S News

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: Genmab reported that its Phase 3 LiGeR-HN1 trial met both primary endpoints. Petosemtamab combined with Merck’s Keytruda significantly improved overall survival and objective response in first-line PD-L1-positive recurrent or metastatic head and neck cancer, cutting the risk of death by 50% versus Keytruda alone. Genmab plans to discuss the results with regulators, supporting the drug’s potential commercial value. Genmab Phase 3 LiGeR-HN1 trial announcement
• Positive Sentiment: Analysts remain constructive following the trial data. Truist reaffirmed a Buy rating and raised its price target to $67 from $45, while HC Wainwright lifted its target to $70 from $50 and maintained its Buy rating. These targets imply additional upside from recent trading levels. HC Wainwright analyst action
• Neutral Sentiment: HC Wainwright’s updated quarterly EPS forecasts were essentially unchanged, with small increases for the fourth quarter of 2026 and the third and fourth quarters of 2027 offset by minor reductions for the first and second quarters of 2027. The firm still expects $1.22 in full-year EPS and retains its Buy rating. Genmab analyst estimates
• Negative Sentiment: After reaching record or 52-week highs on the trial announcement, valuation and near-term profit-taking may be weighing on the shares. Commentary has cautioned investors about buying immediately after the strong run, despite describing the clinical results as compelling. Genmab valuation commentary

Genmab A/S Company Profile

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering and developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including DuoBody and HexaBody, to create therapies designed to engage the immune system or target specific disease-related proteins.

Genmab’s marketed and partnered products include DARZALEX (daratumumab) for multiple myeloma, developed with Johnson & Johnson; EPKINLY (epcoritamab) for certain types of B-cell lymphoma, developed with AbbVie; and Tivdak (tisotumab vedotin) for cervical cancer, developed with Seagen.